Investor directory

Robin Hood Ventures

Robin Hood Ventures is an angel investor group based in Philadelphia, Pennsylvania, established in 1999. The organization focuses on early-stage, high-growth companies primarily in the Greater Philadelphia region. It provides capital, mentoring, and valuable connections to assist entrepreneurs in building successful businesses. Typically, Robin Hood Ventures invests between $250,000 and $500,000, often collaborating with other angel investors, institutions, and venture capitalists within its network. The firm has a diverse investment portfolio, spanning various sectors, including information technology services, software, life sciences, hard technology, consumer products, and financial technology. Since its inception, Robin Hood Ventures has invested in over 45 companies, emphasizing a hands-on approach to helping businesses achieve their potential.
http://www.robinhoodventures.com
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=620046

Donna Cordner

Managing Partner

Allen Fogel

Partner

Ellen Weber

Executive Director

Past deals in Delaware

Virion Therapeutics

Funding Round in 2024
Virion Therapeutics, established in 2018 and based in Newark, Delaware, is a biotechnology company focused on developing immune-based treatments for virally-associated cancers and chronic viral infections. The company's primary products are ChiVax and ChiVax-gD vaccines, designed to induce potent and sustained T cell-mediated immune responses against transformed or infected cells. These vaccines have demonstrated promising results in pre-clinical testing and are poised for translation into clinical trials targeting diseases such as HPV-induced cancers and chronic Hepatitis B infections.

FEMSelect

Convertible Note in 2024
FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.

FEMSelect

Series B in 2022
FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.

FEMSelect

Convertible Note in 2020
FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.

FEMSelect

Convertible Note in 2020
FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.

Virion Therapeutics

Convertible Note in 2019
Virion Therapeutics, established in 2018 and based in Newark, Delaware, is a biotechnology company focused on developing immune-based treatments for virally-associated cancers and chronic viral infections. The company's primary products are ChiVax and ChiVax-gD vaccines, designed to induce potent and sustained T cell-mediated immune responses against transformed or infected cells. These vaccines have demonstrated promising results in pre-clinical testing and are poised for translation into clinical trials targeting diseases such as HPV-induced cancers and chronic Hepatitis B infections.

Virion Therapeutics

Series A in 2018
Virion Therapeutics, established in 2018 and based in Newark, Delaware, is a biotechnology company focused on developing immune-based treatments for virally-associated cancers and chronic viral infections. The company's primary products are ChiVax and ChiVax-gD vaccines, designed to induce potent and sustained T cell-mediated immune responses against transformed or infected cells. These vaccines have demonstrated promising results in pre-clinical testing and are poised for translation into clinical trials targeting diseases such as HPV-induced cancers and chronic Hepatitis B infections.

ThruPore Technologies

Seed Round in 2018
ThruPore Technologies designs and manufactures porous carbon support structures for industrial catalysts, producing heterogeneous catalysts in pellet and powder forms. It focuses on palladium on carbon driven reactions, seeking improved porosity and dispersion within the catalyst support. The company develops high-porosity carbon materials for applications across precious metal and carbon-only catalysts, as well as fuel cell and battery materials, delivering refined end products for industrial clients. The company was founded in 2012 and is headquartered in Bear, Delaware.

FEMSelect

FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.